Limits...
FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy.

Deliyanti D, Zhang Y, Khong F, Berka DR, Stapleton DI, Kelly DJ, Wilkinson-Berka JL - PLoS ONE (2015)

Bottom Line: Macroglial Müller cells, which exhibit a pro-inflammatory and pro-angiogenic phenotype in diabetes, were evaluated in the 8-week study as well as in culture following exposure to hyperglycaemia and FT011 (10, 30, 100 μM) for 72 hours.In Müller cells, FT011 reduced diabetes-induced gliosis and vascular endothelial growth factor (VEGF) immunolabeling and the hyperglycaemic-induced increase in ICAM-1, monocyte chemoattractant protein-1, CCL20, cytokine-induced neutrophil chemoattractant-1, VEGF and IL-6.In conclusion, the protective effects of FT011 in cardiorenal disease extend to key elements of diabetic retinopathy and highlight its potential as a treatment approach.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia, 3004.

ABSTRACT
Diabetic retinopathy features inflammation as well as injury to glial cells and the microvasculature, which are influenced by hypertension and overactivity of the renin-angiotensin system. FT011 is an anti-inflammatory and anti-fibrotic agent that has been reported to attenuate organ damage in diabetic rats with cardiomyopathy and nephropathy. However, the potential therapeutic utility of FT011 for diabetic retinopathy has not been evaluated. We hypothesized that FT011 would attenuate retinopathy in diabetic Ren-2 rats, which exhibit hypertension due to an overactive extra-renal renin-angiotensin system. Diabetic rats were studied for 8 and 32 weeks and received intravitreal injections of FT011 (50 μM) or vehicle (0.9% NaCl). Comparisons were to age-matched controls. In the 8-week study, retinal inflammation was examined by quantitating vascular leukocyte adherence, microglial/macrophage density and the expression of inflammatory mediators. Macroglial Müller cells, which exhibit a pro-inflammatory and pro-angiogenic phenotype in diabetes, were evaluated in the 8-week study as well as in culture following exposure to hyperglycaemia and FT011 (10, 30, 100 μM) for 72 hours. In the 32-week study, severe retinal vasculopathy was examined by quantitating acellular capillaries and extracellular matrix proteins. In diabetic rats, FT011 reduced retinal leukostasis, microglial density and mRNA levels of intercellular adhesion molecule-1 (ICAM-1). In Müller cells, FT011 reduced diabetes-induced gliosis and vascular endothelial growth factor (VEGF) immunolabeling and the hyperglycaemic-induced increase in ICAM-1, monocyte chemoattractant protein-1, CCL20, cytokine-induced neutrophil chemoattractant-1, VEGF and IL-6. Late intervention with FT011 reduced acellular capillaries and the elevated mRNA levels of collagen IV and fibronectin in diabetic rats. In conclusion, the protective effects of FT011 in cardiorenal disease extend to key elements of diabetic retinopathy and highlight its potential as a treatment approach.

No MeSH data available.


Related in: MedlinePlus

FT011M reduced the protein levels of pro-inflammatory and pro-angiogenic factors in Müller cells.NG, normoglycaemia. HG, hyperglycaemia. (A) soluble ICAM-1 (sICAM-1). (B) MCP-1. (C) CCL20. (D) GRO/CINC-1. (E) VEGF. (F) IL-6. (A, C, D, E and F) values are arbitrary units for cytokine array. Values for (B) are pg/ml for ELISA. *P < 0.05, **P < 0.01 and ***P < 0.001 to untreated (-) NG. #P < 0.05, ##P < 0.01 and ###P < 0.001 to untreated (-) HG. Experiments performed in triplicate with 3 samples per experiment. Values are Mean ± SEM.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4519240&req=5

pone.0134392.g005: FT011M reduced the protein levels of pro-inflammatory and pro-angiogenic factors in Müller cells.NG, normoglycaemia. HG, hyperglycaemia. (A) soluble ICAM-1 (sICAM-1). (B) MCP-1. (C) CCL20. (D) GRO/CINC-1. (E) VEGF. (F) IL-6. (A, C, D, E and F) values are arbitrary units for cytokine array. Values for (B) are pg/ml for ELISA. *P < 0.05, **P < 0.01 and ***P < 0.001 to untreated (-) NG. #P < 0.05, ##P < 0.01 and ###P < 0.001 to untreated (-) HG. Experiments performed in triplicate with 3 samples per experiment. Values are Mean ± SEM.

Mentions: In Müller cells exposed to hyperglycaemia, the protein levels of MCP-1, soluble ICAM-1, CCL20, growth-regulated oncogene/cytokine-induced neutrophil chemoattractant-1 (GRO/CINC-1), VEGF and IL-6 were increased compared to normoglycaemic controls (Fig 5). FT011M at concentrations of 10, 30 and 100 μM, reduced the hyperglycaemic-induced increased in these factors, except for CCL20 and IL-6, which were reduced with 30 and 100 μM FT011M (Fig 5).


FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy.

Deliyanti D, Zhang Y, Khong F, Berka DR, Stapleton DI, Kelly DJ, Wilkinson-Berka JL - PLoS ONE (2015)

FT011M reduced the protein levels of pro-inflammatory and pro-angiogenic factors in Müller cells.NG, normoglycaemia. HG, hyperglycaemia. (A) soluble ICAM-1 (sICAM-1). (B) MCP-1. (C) CCL20. (D) GRO/CINC-1. (E) VEGF. (F) IL-6. (A, C, D, E and F) values are arbitrary units for cytokine array. Values for (B) are pg/ml for ELISA. *P < 0.05, **P < 0.01 and ***P < 0.001 to untreated (-) NG. #P < 0.05, ##P < 0.01 and ###P < 0.001 to untreated (-) HG. Experiments performed in triplicate with 3 samples per experiment. Values are Mean ± SEM.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4519240&req=5

pone.0134392.g005: FT011M reduced the protein levels of pro-inflammatory and pro-angiogenic factors in Müller cells.NG, normoglycaemia. HG, hyperglycaemia. (A) soluble ICAM-1 (sICAM-1). (B) MCP-1. (C) CCL20. (D) GRO/CINC-1. (E) VEGF. (F) IL-6. (A, C, D, E and F) values are arbitrary units for cytokine array. Values for (B) are pg/ml for ELISA. *P < 0.05, **P < 0.01 and ***P < 0.001 to untreated (-) NG. #P < 0.05, ##P < 0.01 and ###P < 0.001 to untreated (-) HG. Experiments performed in triplicate with 3 samples per experiment. Values are Mean ± SEM.
Mentions: In Müller cells exposed to hyperglycaemia, the protein levels of MCP-1, soluble ICAM-1, CCL20, growth-regulated oncogene/cytokine-induced neutrophil chemoattractant-1 (GRO/CINC-1), VEGF and IL-6 were increased compared to normoglycaemic controls (Fig 5). FT011M at concentrations of 10, 30 and 100 μM, reduced the hyperglycaemic-induced increased in these factors, except for CCL20 and IL-6, which were reduced with 30 and 100 μM FT011M (Fig 5).

Bottom Line: Macroglial Müller cells, which exhibit a pro-inflammatory and pro-angiogenic phenotype in diabetes, were evaluated in the 8-week study as well as in culture following exposure to hyperglycaemia and FT011 (10, 30, 100 μM) for 72 hours.In Müller cells, FT011 reduced diabetes-induced gliosis and vascular endothelial growth factor (VEGF) immunolabeling and the hyperglycaemic-induced increase in ICAM-1, monocyte chemoattractant protein-1, CCL20, cytokine-induced neutrophil chemoattractant-1, VEGF and IL-6.In conclusion, the protective effects of FT011 in cardiorenal disease extend to key elements of diabetic retinopathy and highlight its potential as a treatment approach.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia, 3004.

ABSTRACT
Diabetic retinopathy features inflammation as well as injury to glial cells and the microvasculature, which are influenced by hypertension and overactivity of the renin-angiotensin system. FT011 is an anti-inflammatory and anti-fibrotic agent that has been reported to attenuate organ damage in diabetic rats with cardiomyopathy and nephropathy. However, the potential therapeutic utility of FT011 for diabetic retinopathy has not been evaluated. We hypothesized that FT011 would attenuate retinopathy in diabetic Ren-2 rats, which exhibit hypertension due to an overactive extra-renal renin-angiotensin system. Diabetic rats were studied for 8 and 32 weeks and received intravitreal injections of FT011 (50 μM) or vehicle (0.9% NaCl). Comparisons were to age-matched controls. In the 8-week study, retinal inflammation was examined by quantitating vascular leukocyte adherence, microglial/macrophage density and the expression of inflammatory mediators. Macroglial Müller cells, which exhibit a pro-inflammatory and pro-angiogenic phenotype in diabetes, were evaluated in the 8-week study as well as in culture following exposure to hyperglycaemia and FT011 (10, 30, 100 μM) for 72 hours. In the 32-week study, severe retinal vasculopathy was examined by quantitating acellular capillaries and extracellular matrix proteins. In diabetic rats, FT011 reduced retinal leukostasis, microglial density and mRNA levels of intercellular adhesion molecule-1 (ICAM-1). In Müller cells, FT011 reduced diabetes-induced gliosis and vascular endothelial growth factor (VEGF) immunolabeling and the hyperglycaemic-induced increase in ICAM-1, monocyte chemoattractant protein-1, CCL20, cytokine-induced neutrophil chemoattractant-1, VEGF and IL-6. Late intervention with FT011 reduced acellular capillaries and the elevated mRNA levels of collagen IV and fibronectin in diabetic rats. In conclusion, the protective effects of FT011 in cardiorenal disease extend to key elements of diabetic retinopathy and highlight its potential as a treatment approach.

No MeSH data available.


Related in: MedlinePlus